Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghong Zhou

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|November 3, 2021
Phase 3 Trial of mRNA-1273 during the Delta-Variant SurgeLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
Medrxiv : the Preprint Server for Health Sciences|October 6, 2021
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant SurgeLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
Nature Medicine|August 31, 2023
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSpyros Chalkias, Jordan L Whatley, Frank Eder, et al.
The Journal of Infectious Diseases|May 10, 2022
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) TrialHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Nature Communications|August 29, 2024
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phasesLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2024
Safety and Immunogenicity of an mRNA-1273 Booster in ChildrenVladimir Berthaud, C Buddy Creech, Christina A Rostad, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
The New England Journal of Medicine|May 11, 2022
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of AgeC Buddy Creech, Evan Anderson, Vladimir Berthaud, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|November 3, 2021
Phase 3 Trial of mRNA-1273 during the Delta-Variant SurgeLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
Medrxiv : the Preprint Server for Health Sciences|October 6, 2021
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant SurgeLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
Nature Medicine|August 31, 2023
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSpyros Chalkias, Jordan L Whatley, Frank Eder, et al.
The Journal of Infectious Diseases|May 10, 2022
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) TrialHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Nature Communications|August 29, 2024
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phasesLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2024
Safety and Immunogenicity of an mRNA-1273 Booster in ChildrenVladimir Berthaud, C Buddy Creech, Christina A Rostad, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
The New England Journal of Medicine|May 11, 2022
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of AgeC Buddy Creech, Evan Anderson, Vladimir Berthaud, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Pageof 10